CHARLOTTESVILLE, Va., May 20, 2020 -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new.

The LA County Fire Department has informed us that, due to the necessity to respond to the pandemic, it is suspending future training of first responders who had been scheduled to participate in the trial protocol. Such disruptions are expected to delay the Company’s previously announced timeline for study completion.

CHARLOTTESVILLE, Va., April 01, 2020 -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new.

The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, were approximately $12.0 million. Diffusion currently intends to use the net proceeds from the offering to fund research and development of its lead product candidate, TSC, including clinical trial activities, and for general corporate purposes.

Dr. Gainer will continue to serve as both an advisor to the Company and as a member of the board of directors. In recognition of the advancement of the TSC technology into the clinic, the Company has begun a search for a Chief Medical Officer as a replacement for the former Chief Science Officer position.

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Encouraging Data for Dose Escalation Run-in of Phase 3 GBM Trial On December 10, 2019, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced the presentation of highly encouraging data from the 19 patient run-in portion of the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial of TSC in

$16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 18, 2020 -- In the news release.

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Waiting for Response on Pre-IND Submission for TSC in COVID-19 ARDS On April 27, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced the company’s Pre-IND submission to the U.S. FDA for the use of the company’s lead development compound, trans sodium crocetinate (TSC), for the treatment of acute

CHARLOTTESVILLE, Va., May 11, 2020 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new.

$16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 17, 2020 -- Diffusion.

The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, are expected to be approximately $12.0 million. The closing is expected to occur on or about May 20, 2020, subject to the satisfaction of customary closing conditions. Diffusion currently intends to use the net proceeds from the offering to fund research and development of its lead product candidate, TSC, including clinical trial activities, and for general corporate purposes.

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles Simultaneous patient enrollment planned in both the U.S. and.

Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating TSC as Treatment for ARDS On April 1, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the company will be evaluating its lead development compound, trans sodium crocetinate (TSC), for the treatment of acute respiratory distress syndrome (ARDS) as a result of infection with the novel

CHARLOTTESVILLE, Va., Jan. 10, 2020 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company.

The PIND was filed on April 27, seeking FDA guidance on the Company’s proposed clinical development program for the use of trans sodium crocetinate (TSC) in COVID-19 patients displaying severe respiratory symptoms and low oxygen levels. The FDA’s accelerated response to the PIND meeting request recommended that the first U.S. TSC COVID-19 study employ a double-blinded, controlled, randomized clinical trial design to address the wide variability in standard of care due to the rapidly evolving COVID-19 experience.

Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

This patent relates to pharmaceutical compositions of trans sodium crocetinate (“TSC”) and a cyclodextrin for use in therapy. Specifically claimed are TSC compositions are for use in conjunction with radiation or chemotherapy. Secondary claims relate to various compositions of TSC.

Under federal regulations, the FDA has up to 60 days to hold an advisory meeting with the Company, but for COVID-19-related submissions, the FDA has announced its intention to significantly shorten this period under its Coronavirus Treatment Acceleration Program. Clinical trial start-up preparations are continuing as the Company awaits the FDA’s response.